Abstract:Since the onset of the COVID-19 pandemic, a variety of diagnostic approaches, including RT-qPCR, RAPID, and LFA, have been adopted, with RT-qPCR emerging as the gold standard. However, a significant challenge in COVID-19 diagnostics is the wide range of symptoms presented by patients, necessitating early and accurate diagnosis for effective management. Although RT-qPCR is a precise molecular technique, it is not immune to false-negative results. In contrast, CRISPR-based detection methods for SARS-CoV-2 offer several advantages: they are cost-effective, time-efficient, highly sensitive, and specific, and they do not require sophisticated instruments. These methods also show promise for scalability, enabling diagnostic tests. CRISPR technology can be customized to target any genomic region of interest, making it a versatile tool with applications beyond diagnostics, including therapeutic development. The CRISPR/Cas systems provide precise gene targeting with immense potential for creating next-generation diagnostics and therapeutics. One of the key advantages of CRISPR/Cas-based therapeutics is the ability to perform multiplexing, where different sgRNAs or crRNAs can target multiple sites within the same gene, reducing the likelihood of viral escape mutants. Among the various CRISPR systems, CRISPR/Cas13 and CARVER (Cas13-assisted restriction of viral expression and readout) are particularly promising. These systems can target a broad range of single-stranded RNA viruses, making them suitable for the diagnosis and treatment of various viral diseases, including SARS-CoV-2. However, the efficacy and safety of CRISPR-based therapeutics must be thoroughly evaluated in pre-clinical and clinical settings. While CRISPR biotechnologies have not yet been fully harnessed to control the current COVID-19 pandemic, there is an optimism that the limitations of the CRISPR/Cas system can be overcome soon. This review discusses how CRISPR-based strategies can revolutionize disease diagnosis and therapeutic development, better preparing us for future viral threats.

CRISPR‐based point‐of‐care diagnostics incorporating Cas9, Cas12, and Cas13 enzymes advanced for SARS‐CoV‐2 detection

Advanced CRISPR-Cas Effector Enzyme-Based Diagnostics for Infectious Diseases, Including COVID-19

Rapid detection of SARS-CoV-2 with CRISPR-Cas12a

SARS-CoV-2 Detection with CRISPR Diagnostics

CRISPR‐Cas system: A promising tool for rapid detection of SARS‐CoV‐2 variants

FnCas9-based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV-2 variants on a paper strip

Harnessing CRISPR-Cas to Combat COVID-19: From Diagnostics to Therapeutics

CRISPR-cas technology: A key approach for SARS-CoV-2 detection

Advancing CRISPR-Based Solutions for COVID-19 Diagnosis and Therapeutics

Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic

CRISPR-Based COVID-19 Testing: Toward Next-Generation Point-of-Care Diagnostics

Development and application of sensitive, specific, and rapid CRISPR‐Cas13‐based diagnosis

Point of Care Diagnostic Devices for Rapid Detection of Novel Coronavirus (SARS-nCoV19) Pandemic: A Review

Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application

CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics

Next-Generation Molecular Diagnostics Development by CRISPR/Cas Tool: Rapid Detection and Surveillance of Viral Disease Outbreaks

A CRISPR-based and Post-Amplification Coupled SARS-CoV-2 Detection with a Portable Evanescent Wave Biosensor

opvCRISPR: One-pot visual RT-LAMP-CRISPR platform for SARS-cov-2 detection

Clinical validation of engineered CRISPR/Cas12a for rapid SARS-CoV-2 detection

CRISPR-cas systems based molecular diagnostic tool for infectious diseases and emerging 2019 novel coronavirus (COVID-19) pneumonia